- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
36
36 companies
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$512.39
7D
-3.7%
1Y
56.8%
Axsome Therapeutics
Market Cap: US$9.3b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$185.96
7D
-1.6%
1Y
75.0%
Travere Therapeutics
Market Cap: US$3.8b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$40.50
7D
-0.7%
1Y
120.9%
Zevra Therapeutics
Market Cap: US$597.7m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.08
7D
-5.5%
1Y
40.0%
Syndax Pharmaceuticals
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.39
7D
-11.7%
1Y
60.5%
Insmed
Market Cap: US$31.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$135.17
7D
-6.4%
1Y
94.0%
Rhythm Pharmaceuticals
Market Cap: US$5.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$85.70
7D
-3.4%
1Y
34.4%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.95
7D
-7.8%
1Y
13.1%
Pelthos Therapeutics
Market Cap: US$77.8m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.06
7D
0.2%
1Y
69.6%
Capricor Therapeutics
Market Cap: US$2.0b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$35.27
7D
1.6%
1Y
170.7%
Aldeyra Therapeutics
Market Cap: US$96.3m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.55
7D
-13.9%
1Y
-41.7%
ARS Pharmaceuticals
Market Cap: US$824.2m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.29
7D
1.3%
1Y
-39.8%
CG Oncology
Market Cap: US$5.9b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$68.68
7D
-6.5%
1Y
207.0%
Kiniksa Pharmaceuticals International
Market Cap: US$3.3b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$42.79
7D
-4.7%
1Y
100.3%
AC Immune
Market Cap: US$294.6m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.84
7D
-5.6%
1Y
73.2%
Arcutis Biotherapeutics
Market Cap: US$2.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.26
7D
-5.2%
1Y
59.2%
Vera Therapeutics
Market Cap: US$2.8b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$37.69
7D
-10.9%
1Y
62.3%
Neurocrine Biosciences
Market Cap: US$12.8b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$127.68
7D
-4.2%
1Y
19.6%
SIGA Technologies
Market Cap: US$324.5m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.57
7D
-4.0%
1Y
-29.7%
Belite Bio
Market Cap: US$6.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$161.26
7D
-2.5%
1Y
176.9%
Verrica Pharmaceuticals
Market Cap: US$111.5m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.98
7D
10.4%
1Y
42.7%
Praxis Precision Medicines
Market Cap: US$9.2b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$344.82
7D
0.7%
1Y
857.8%
BeOne Medicines
Market Cap: US$33.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$300.80
7D
-7.1%
1Y
22.8%
Unicycive Therapeutics
Market Cap: US$185.5m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.29
7D
3.8%
1Y
13.9%
Benitec Biopharma
Market Cap: US$435.0m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.37
7D
-12.1%
1Y
-9.0%
Gyre Therapeutics
Market Cap: US$679.4m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.44
7D
-8.1%
1Y
-18.0%
Fennec Pharmaceuticals
Market Cap: US$229.6m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.84
7D
0.7%
1Y
21.5%
Mirum Pharmaceuticals
Market Cap: US$5.5b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$91.49
7D
-6.6%
1Y
124.2%
Fortress Biotech
Market Cap: US$71.8m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.33
7D
-1.3%
1Y
42.1%
Journey Medical
Market Cap: US$141.0m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.15
7D
-4.5%
1Y
-31.1%
Protagonist Therapeutics
Market Cap: US$6.5b
Operates as a discovery and development company in the United States.
PTGX
US$100.00
7D
-5.6%
1Y
124.8%
Geron
Market Cap: US$961.4m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.50
7D
-10.7%
1Y
5.6%
Prothena
Market Cap: US$577.6m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.75
7D
-1.4%
1Y
10.8%
Dyadic International
Market Cap: US$31.6m
A biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
DYAI
US$0.86
7D
-1.7%
1Y
-27.1%
Inovio Pharmaceuticals
Market Cap: US$93.4m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.15
7D
-3.4%
1Y
-38.5%
Legend Biotech
Market Cap: US$4.4b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$23.90
7D
12.9%
1Y
-30.3%